Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

103
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
103
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

84
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
84
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

78
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
78
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

702
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
702
Drug Therapy01:28

Drug Therapy

154
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
154
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

590
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
590

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "The effect of continuous or intermittent calorie-restricted diet on body composition and resting energy expenditure in patients with type 2 diabetes"[Clin Nutr ESPEN 72 (2026) 102940].

Clinical nutrition ESPEN·2026
Same author

Talking with pediatric patients with overweight or obesity and their parents: self-rated self-efficacy and perceived barriers of Dutch healthcare professionals from seven disciplines.

BMC health services research·2022
Same author

Study protocol: DexaDays-2, hydrocortisone for treatment of dexamethasone-induced neurobehavioral side effects in pediatric leukemia patients: a double-blind placebo controlled randomized intervention study with cross-over design.

BMC pediatrics·2021
Same author

[Intermittent fasting in science and practice; what are the effects on weight and cardiometabolic health?]

Nederlands tijdschrift voor geneeskunde·2021
Same author

Appetite- and weight-inducing and -inhibiting neuroendocrine factors in Prader-Willi syndrome, Bardet-Biedl syndrome and craniopharyngioma versus anorexia nervosa.

Endocrine connections·2021
Same author

Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity.

Endocrine·2021

Related Experiment Video

Updated: Nov 18, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

654

[Pharmacotherapy for obesity].

E F C van Rossum1,2, M S Welling1, B van der Voorn1

  • 1Erasmus MC, afd. Interne Geneeskunde, Rotterdam.

Nederlands Tijdschrift Voor Geneeskunde
|February 9, 2021
PubMed
Summary
This summary is machine-generated.

Obesity is a complex endocrine disease requiring multifaceted treatment. Lifestyle changes are key, with newer medications like liraglutide offering significant additional weight loss for many patients.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

820
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.8K

Related Experiment Videos

Last Updated: Nov 18, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

654
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

820
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.8K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Obesity is a complex endocrine disorder influenced by environmental, behavioral, and biological factors.
  • Weight loss maintenance is challenging due to neuro-endocrine adaptations that promote weight regain.
  • Identifying diverse contributing factors, including medications, psychological issues, endocrine imbalances, and monogenic obesity, is crucial.

Purpose of the Study:

  • To review current understanding and treatment strategies for obesity.
  • To highlight the role of lifestyle interventions and emerging pharmacotherapies.
  • To discuss management of rare obesity forms and future drug development.

Main Methods:

  • Review of current literature on obesity etiology and treatment.
  • Analysis of the efficacy of combined lifestyle intervention (CLI).
  • Evaluation of novel pharmacotherapies such as liraglutide 3 mg and naltrexone/bupropion.

Main Results:

  • Achieving a 5% weight loss offers significant health benefits.
  • Novel pharmacotherapies (liraglutide 3 mg, naltrexone/bupropion) provide an additional 5-6% mean weight loss over CLI alone.
  • Targeted therapies exist for rare obesity forms, with new treatments under development.

Conclusions:

  • Obesity management requires addressing lifestyle and all contributing factors.
  • Pharmacotherapy and bariatric surgery are options for high-risk patients unresponsive to lifestyle changes.
  • Advancements in pharmacotherapy offer new avenues for effective obesity treatment.